Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma

Cancer Investigation

Volumn 26, Issue 10, 2008, Pages 1024-1031

  Hornychova, Helena ^a   Melichar, Bohuslav ^a,b   Tomšova, Marketa ^a   Mergancová, Jindiška ^a   Urminská, Hana ^a   Ryška, Ales ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast cancers; Chemotherapy; Immunology immunobiology; Prognosis and response predictions

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD83 ANTIGEN; DOXORUBICIN; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN S 100; T6 ANTIGEN; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MASTECTOMY; MONOCYTE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 57749185261     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802098165     Document Type: Article

References (51)

1. Veronesi, U.; Boyle, P.; Goldhirsch, A.; Orecchia, R.; Viale, G. Breast cancer. Lancet 2005, 365, 1727-1741.
2. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365, 1687-1717.
3. Estevez, L.G.; Gradishar, W.J. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004, 10, 3249-3261.
4. Kaufmann, M.; Hortobagyi, G.N.; Goldhirsch, A., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006, 24, 1940-1949.
5. Jassem, J.; Pienkowski, T.; Pluzanska, A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001, 19, 1707-1715.
6. Dieras, V.; Fumoleau, P.; Romieu, G., et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004, 22, 4958-4965.
7. Faneyte, I.F.; Schrama, J.G.; Peterse, J.L.; Remijnse, P.L.; Rodenhuis, S.; van de Vijver, M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003, 88, 406-412.
8. Kandioler-Eckersberger, D.; Ludwig, C.; Rudas, M., et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000, 6, 50-56.
9. Bouchalova, K.; Trojanec, R.; Kolár, Z., et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 2006, 53, 393-401.
10. Murta, E.F.C.; de Andrade, J.M.; Falcao, R.P.; Bighetti, S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 2000, 86, 403-407.
11. Pusztai, L.; Mendoza, T.R.; Reuben, J.M., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25, 94-102.
12. Tsavaris, N.; Kosmas, C.; Vadiaka, M.; Kanelopoulos, P.; Boulamatsis, D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002, 87, 21-27.
13. Melichar, B.; Touskova, M.; Hornychova, H., et al. Systemic immune activation and peripheral blood lymphocytes during primary chemotherapy with the combination of doxorubicin and paclitaxel. Pteridines 2007, 18, 25-34.
14. Tavasoli, F.A.; Deviler, P. Pathology and genetics of tumours of the breast and female genital organs: In: Kleinhues, P.; Sogin, L.H. World Health Organisation Classification of Tumours. IARC Press: Lyon, 2003.
15. Chevallier, B.; Roche, H.; Olivier, J.P.; Chollet, P.; Hurteloup, P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in high histologic response rate. Am. J. Clin. Oncol 1993, 16, 223-228.
16. Remmele, W.; Stegner, H.E. Vorschlag zu einheitlichen Definition eines immunoreactives Score (IRS) fur immunhistochemischen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 1987, 8, 138-140.
17. Weidner, N.; Semple, J.P.; Welch, W.R.; Folkman, J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991, 324, 1-8.
18. + tumor-infiltrating lymphocytes in ovarian carcinoma. Gyn Oncol 2008, 108, 415-420.
19. Demaria, S.; Volm, M.D.; Shapiro, R.L., et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001, 7, 3025-3030.
20. Lucin, K.; Iternicka, Z.; Jonjic, N. Prognostic significance of T-cell infiltrates, expression of beta2.microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1994, 190, 1134-1140.
21. Wang, B.L.; Springer, G.F.; Kaufmamn, M.W. Concurrent immunohistochemical staining of tumor-infiltrating lymphocytes and carcinoma-associated T (Thomsen-Friedenreich) Tn antigens in human breast carcinoma. J Histochem Cytochem 1996, 44, 187-191.
22. Georgiannos, S.N.; Renaut, A.; Goode, A.W.; Sheaff, M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their associatin with prognostic indicators. Surgery 2003, 134, 827-834.
23. Leong, P.P.; Mohammad, R.; Ibrahim, N., et al. Phenotyping of lymphocytes exxpressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006, 102, 229-236.
24. Wong, P.Y.; Staren, E.D.; Tereshkova, N.; Braun, D.P. Functional analysis of tumor-infiltrating lekocytes in breast cancer patients. J Surg Res 1998, 76, 95-103.
25. Menard, S.; Tomasic, G.; Casalini, P., et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997, 3, 817-819.
26. Iwamoto, M.; Shinohara, H.; Miyamoto, A., et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003, 104, 92-97.
27. Ueno, T.; Toi, M.; Saji, H., et al. Significance of macrophage chemico attractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000, 6, 3282-3289.
28. Lewis, J.S.; Landers, R.J.; Underwood, C.E.; Harris, A.L.; Lewis, C.E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000, 192, 150-158.
29. Pupa, S.M.; Bufalino, R.; Invernizzi, A.M., et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996, 14, 85-94.
30. O'Sullivan, C.; Lewis, C.E. Tumor-associated leucocytes: friends or foes in breast carcinoma. J Pathol 1994, 172, 229-235.
31. Parshad, R.; Kapoor, S.; Gupta, S.D.; Kumar, A.; Chattopadhyaya, T.K. Does famotidine enhance tumor-infiltrating lymphocytes in breast cancer? Acta Oncol 2002, 2002, 362-365.
32. Chollet, P.; Amat, S.; Cure, H., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86, 1041-1046.
33. Bear, H.D.; Anderson, S.; Smith, R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006, 24, 2019-2027.
34. Machiavelli, M.R.; Romero, A.O.; Perez, J.E., et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998, 4, 125-131.
35. Thomas, E.; Holmes, F.A.; Smith, T.L., et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective, randomized trial. J Clin Oncol 2004, 22, 2294-2302.
36. Arnould, L.; Gelly, M.; Penault-Llorca, F., et al. Trastuzumab-based treatment of HER2-positive breast cancer an antibody-dependent cellular cyotoxicity mechanism? Br J Cancer 2006, 94, 259-267.
37. Chang, J.C.; Wooten, E.C.; Tsimelzon, A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362, 362-369.
38. van de Vijver, M.J.; He, Y.F.; van't Veer, L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347, 1999-2009.
39. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9, 271-296.
40. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 2001, 357, 539-545.
41. Elgert, K.D.; Alleva, D.G.; Mullins, D.W. Tumor-induced immune dysfunction: the macrophage connection. J Leukocyte Biol 1998, 64, 275-290.
42. Alleva, D.G.; Burger, C.J.; Elgert, K.D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E. J Immunol 1994, 153, 1674-1686.
43. Uyttenhove, C.; Pilotte, L.; Theate, I., et al. Evidence for a tumor immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9, 1269-1274.
44. Dales, J.P.; Garcia, S.; Bonnier, P., et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Am J Clin Pathol 2003, 119, 374-380.
45. Mackall, C.L. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Oncologist 1999, 4, 370-378.
46. Sewell, H.F.; Halbert, C.F.; Robins, R.A.; Galvin, A.; Chan, S.; Blamey, W. Chemotherapy-induced differential changes in lymphocyte subsets nad natural-killer-cell function in patients with advanced breast cancer. Int J Cancer 1993, 55, 735-738.
47. Bogdan, C.; Ding, A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor-alpha and interleukin-1 in macrophages. J Leukocyte Biol 1992, 52, 119-121.
48. Allen, J.N.; Moore, S.A.; Wewers, M.D. Taxol enhances but does not induce interleukin-1-beta and tumor necrosis factor-alfa production. J Lab Clin Med 1993, 122, 374-381.
49. Mullins, D.W.; Burger, C.J.; Elgert, K.D. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999, 162, 6811-6818.
50. Melichar, B.; Solichova, D.; Melicharova, K.; Cermanova, M.; Urminska, H.; Ryska, A. Systemic immune activation, anemia, and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel. Pteridines 2006, 17, 107-114.
51. Carson, W.E.; Shapiro, C.L.; Crespin, T.R.; Thornton, L.M.; Andersen, B.L. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 2004, 10, 3401-3409.